Discovery and validation of human genomic safe harbor sites for gene and cell therapies

Cell Rep Methods. 2022 Jan 14;2(1):100154. doi: 10.1016/j.crmeth.2021.100154. eCollection 2022 Jan 24.

Abstract

Existing approaches to therapeutic gene transfer are marred by the transient nature of gene expression following non-integrative gene delivery and by safety concerns due to the random mechanism of viral-mediated genomic insertions. The disadvantages of these methods encourage future research in identifying human genomic sites that allow for durable and safe expression of genes of interest. We conducted a bioinformatic search followed by the experimental characterization of human genomic sites, identifying two that demonstrated the stable expression of integrated reporter and therapeutic genes without malignant changes to the cellular transcriptome. The cell-type agnostic criteria used in our bioinformatic search suggest widescale applicability of identified sites for engineering of a diverse range of tissues for clinical and research purposes, including modified T cells for cancer therapy and engineered skin to ameliorate inherited diseases and aging. In addition, the stable and robust levels of gene expression from identified sites allow for the industry-scale biomanufacturing of proteins in human cells.

Keywords: criteria; durability; expression; genomic safe harbor; knock-in; safety; transcriptomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Gene Transfer Techniques
  • Genome, Human* / genetics
  • Genomics
  • Humans
  • Proteins*
  • Transgenes

Substances

  • Proteins